Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02717572 | 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR | completed | Phase 1 | 19 | Washington University School of MedicineOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT00670488 | Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002) | completed | Phase 1 | 104 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 1, 2019 | clinicaltrials |
| NCT02048488 | A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 72 | Tesaro, Inc.INDUSTRY | 5 | Mar 26, 2019 | clinicaltrials |
| NCT01844583 | Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib | completed | Phase 1 | 55 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 25, 2019 | clinicaltrials |
| NCT02341456 | Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | completed | Phase 1 | 19 | AstraZenecaINDUSTRY | 3 | Mar 25, 2019 | clinicaltrials |
| NCT03333824 | Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer | completed | Phase 1 | 33 | AstraZenecaINDUSTRY | 1 | Mar 25, 2019 | clinicaltrials |
| NCT01949688 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 26 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01215916 | A Phase 1 Study in Patients With Solid Tumors | completed | Phase 1 | 39 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 15, 2019 | clinicaltrials |
| NCT01512758 | A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 36 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 15, 2019 | clinicaltrials |
| NCT02045095 | A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors | terminated | Phase 1 | 29 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT00002902 | Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 13, 2019 | clinicaltrials |
| NCT02414516 | A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 17 | Oncolys BioPharma IncINDUSTRY | 1 | Mar 13, 2019 | clinicaltrials |
| NCT00962091 | Study of MLN8237 in Participants With Advanced Solid Tumors | completed | Phase 1 | 53 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 12, 2019 | clinicaltrials |
| NCT02161770 | Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment | completed | Phase 1 | 30 | AstraZenecaINDUSTRY | 6 | Mar 8, 2019 | clinicaltrials |
| NCT01341457 | A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors | completed | Phase 1 | 17 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 1, 2019 | clinicaltrials |
| NCT01431534 | A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056) | terminated | Phase 1 | 20 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 1, 2019 | clinicaltrials |
| NCT01713972 | Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors | completed | Phase 1 | 23 | Manisha ShahOTHER | 1 | Mar 1, 2019 | clinicaltrials |
| NCT02070406 | Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies | terminated | Phase 1 | 4 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2019 | clinicaltrials |
| NCT00711243 | Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor | completed | Phase 1 / Phase 2 | 59 | Northwestern UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT02301754 | INVAC-1 Anti-Cancer hTERT DNA Immunotherapy | completed | Phase 1 | 26 | InvectysINDUSTRY | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00892385 | Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 66 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03844438 | A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Luye Pharma Group Ltd.INDUSTRY | 1 | Feb 20, 2019 | clinicaltrials |
| NCT00547677 | Stereotactic Radiosurgery for Patients With Hepatic Metastases. | completed | Phase 1 | 27 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01094288 | A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen | completed | Phase 1 | 41 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01049893 | Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors | completed | Phase 1 | 45 | Daiichi SankyoINDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT01149720 | Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors | completed | Phase 1 | 24 | Daiichi SankyoINDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT01517399 | Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects | completed | Phase 1 | 28 | Daiichi SankyoINDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT01588678 | A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 32 | Daiichi SankyoINDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT01699061 | Effect of Tivantinib on the QTC Interval in Cancer Subjects | completed | Phase 1 | 38 | Daiichi SankyoINDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02076451 | Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 32 | Daiichi SankyoINDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02150733 | Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | completed | Phase 1 | 29 | Daiichi SankyoINDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02179918 | A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) | completed | Phase 1 | 23 | PfizerINDUSTRY | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01999738 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | completed | Phase 1 | 93 | EndocyteINDUSTRY | 1 | Feb 7, 2019 | clinicaltrials |
| NCT02216409 | Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody | completed | Phase 1 | 88 | Gilead SciencesINDUSTRY | 1 | Feb 5, 2019 | clinicaltrials |
| NCT01858155 | Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors | completed | Phase 1 | 9 | C17 CouncilOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT02171221 | Phase I Study of Oral DFP-11207 in Solid Tumors | completed | Phase 1 | 23 | Delta-Fly Pharma, Inc.INDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT03618043 | Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer | unknown | Phase 1 | 14 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT02171260 | This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas(BOLD 113) | completed | Phase 1 | 23 | Eisai Inc.INDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT02963389 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients | completed | Phase 1 | 27 | Dong-A ST Co., Ltd.INDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT02968485 | Phase I Study of SHR7390 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT00005639 | Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 1 | 34 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT01284335 | A Safety Study in Participants With Advanced Solid Tumors | terminated | Phase 1 | 234 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT00785538 | A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available | completed | Phase 1 | 24 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02583165 | A Study in Adult Subjects With Select Advanced Solid Tumors | completed | Phase 1 | 40 | MedImmune LLCINDUSTRY | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02122770 | Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors | completed | Phase 1 | 51 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 7, 2019 | clinicaltrials |
| NCT01214668 | Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors | completed | Phase 1 | 31 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 4, 2019 | clinicaltrials |
| NCT01923337 | Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | completed | Phase 1 | 17 | University of California, DavisOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT01078649 | Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 | 51 | Debiopharm International SAINDUSTRY | 1 | Dec 27, 2018 | clinicaltrials |
| NCT02683395 | A Study of PLX51107 in Advanced Malignancies | terminated | Phase 1 | 50 | PlexxikonINDUSTRY | 1 | Dec 24, 2018 | clinicaltrials |
| NCT01128842 | A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor | completed | Phase 1 | 7 | Puma Biotechnology, Inc.INDUSTRY | 1 | Dec 19, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Apr 5, 2019source: clinicaltrials